Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 11/20 | 0.45 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.45 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.45 |
| ▸ | CHRNB3 | Q05901 | 2/20 | 0.40 |
| ▸ | CHRNA6 | Q15825 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080409 | 0.86 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB3 | |
| SCHEMBL2081281 | 0.83 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB3 | |
| SCHEMBL2078445 | 0.82 | HTR2C (0.46) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB3 | |
| SCHEMBL2082354 | 0.81 | CHRNA3 (0.51) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB3 | |
| SCHEMBL2080785 | 0.80 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB3 | |
| SCHEMBL2081182 | 0.80 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB3 | |
| SCHEMBL4881754 | 0.77 | HTR2C (0.59) | CHRNB2CHRNA4CHRNA3CHRNB4HTR2C | |
| SCHEMBL2079428 | 0.77 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNA3CHRNB4 | |
| SCHEMBL2080220 | 0.76 | CHRNB2 (0.45) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB3 | |
| SCHEMBL2082358 | 0.76 | CHRNA3 (0.47) | CHRNB2CHRNA4CHRNA3CHRNB4CHRNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897611-B2 | Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders | TARGACEPT, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-20100179183-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| US-20100152228-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| EP-1678172-B1 | AZABICYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT INC (US) | 2009-12-09 | — | — | EP | disclosed |
| US-20080242693-A1 | Pharmaceutical Compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders | TARGACEPT, INC. (US) | 2008-10-02 | — | — | US | disclosed |
| US-7402592-B2 | Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders | TARGACEPT, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1678172-A2 | AZABICYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Targacept, Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005037832-A9 | AZABICYCYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | — | 2006-01-26 | — | — | WO | disclosed |
| US-20050282823-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| WO-2005037832-A2 | AZABICYCYCLIC COMPOUNDS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242693-A1 | Pharmaceutical Compositions and Methods for Relieving Pain and Treating Central Nervous System Disorders | OPRL1, OPRK1, COMT | CHRNB2 25/4885CHRNA4 68/4885CHRNA3 44/4885 |
| US-20050282823-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | OPRL1, OPRK1, COMT | CHRNB2 25/4885CHRNA4 68/4885CHRNA3 44/4885 |
| US-20100179183-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | OPRL1, OPRK1, COMT | CHRNB2 25/4885CHRNA4 68/4885CHRNA3 44/4885 |
| US-20100152228-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEVING PAIN AND TREATING CENTRAL NERVOUS SYSTEM DISORDERS | OPRL1, OPRK1, COMT | CHRNB2 25/4885CHRNA4 68/4885CHRNA3 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.